Introduction
It is important to predict human pharmacokinetics (PK) and metabolism of drug candidates in the pre-clinical stage of pharmaceuticals development. Various approaches to predict human clearance (CL) with in vitro metabolic systems, such as human liver microsomes and hepatocytes, have been reported (Nagilla et al., 2006 , Brown et al., 2007 , Fagerholm 2007 , Stringer et al., 2008 , Chiba et al., 2009 , Hallifax et al., 2010 , but with limited success. One of the reasons for the discrepancy between predicted and observed CL may be that the preparation, storage and experimental treatment of hepatocytes alters the normal function of metabolic enzymes (Wang et al., 2005) . Although this might be ameliorated by using fresh hepatocytes immediately after isolation from liver, these are not readily available, and in any case show considerable inter-individual differences. The replacement index (RI) was determined by measurement of human albumin in blood collected from the tail vein. The RI was estimated by the correlation curve between the human albumin levels in mouse blood and determined by using human-specific cytokeratin 8/18-immunostained liver sections (Tateno et al., 2004) . The RI values of PXB mice used in this study ranged from 73.4% to 93.4%.
Administration
Drug solution (5 mL/kg) was administered intravenously (i.v.) to PXB mice at 0.3-5 mg/kg body weight. Solutions of dapsone, diclofenac, 6-deoxypenciclovir, fasudil, ketoprofen, ibuprofen, mirtazapine, naproxen, salbutamol, sulindac were prepared in saline. In the cases of ketoprofen, ibuprofen, naproxen, and sulindac, equivalent amounts of alkali were added.
Dapsone solutions contained 10% dimethylsulfoxide (DMSO), and mirtazapine solutions were prepared with 10% DMSO and equivalent amounts of hydrochloric acid. Lamotrigine, and zaleplon solutions were prepared with 10% DMSO and 10% polyethylene glycol 400 (PEG400) in saline. Equivalent amounts of hydrochloric acid were also added to the solutions of lamotrigine and zaleplon. Warfarin was formulated in 3% DMSO, 97% saline with an equivalent amount of sodium hydroxide.
Blood samples after dosing were collected from an orbital vein of PXB mice at predetermined
times using heparinized glass. These samples were centrifuged and the plasma was stored at -30 ºC.
Determination of drug concentration in plasma
A 10 μL aliquot of plasma was added to 40 μL of acetonitrile or methanol containing an internal standard (carbanazepine, ketoprofen, ibuprofen). The mixtures were centrifuged at 14000 g for 5 min, and the supernatant was subjected to LC/MS/MS.
Isolation and purification of hepatocytes from PXB mice
Fresh hepatocytes were isolated from PXB mice (13-15 weeks of age) by means of the in situ collagenase perfusion method and purified as described (Yamasaki et al, 2010 The final concentration of acetonitrile was 0.5% (v/v) in the reaction mixture. The plates (24 wells) were shaken gently with an orbital shaker. The incubation mixture was sampled at 0, 0.25, 0.5, 1, and 2 hrs after treatment and reactions were stopped by freezing the mixture in liquid nitrogen. When required, the samples were thawed, spiked with 2 volumes of acetonitrile or methanol containing internal standard and centrifuged. Aliquots of the supernatants were subjected to LC/MS/MS.
LC/MS/MS conditions
Aliquots ( 
Determination of PK parameters
Pharmacokinetic parameters were determined by non-compartmental methods using the This article has not been copyedited and formatted. The final version may differ from this version. concentration-time curve profile. The total clearances (CL t ) after i.v. administration were calculated as Dose/AUC iv . AUC iv were estimated from the time course using the trapezoidal method with extrapolation from the last quantifiable point to infinity. The terminal elimination half-life t 1/2 was estimated as ln2/ke, where ke is that of the plot of the terminal elimination phase on a logarithmic scale.
Calculation of in vitro intrinsic clearance
In vitro intrinsic clearance (CL int,in vitro ) was calculated from the time course of disappearance of the test drug during incubation with h-hepatocytes. Each plot was fitted to the first-order elimination rate constant as follows:
where C(t) and C0 are the concentration of unchanged test drug at incubation time t and that compounds, CL int,in vivo was predicted with a 3-to 10-fold error.
Relationship between intrinsic clearance in humans and PXB mice in vivo
We directly compared CL int, in vivo calculated based on a well-stirred model in humans and PXB mice. As shown in Fig. 5 , there was a good correlation (r 2 =0.785, p=5.556 x 10 -5 )
between literature CL int,in vivo in human and measured CL int,in vivo of PXB mice for these compounds. For 4 of 13 (31%) compounds, observed CL int, in vivo in humans was predicted within 3-fold error from PXB mouse CL int, in vivo . For 7 of 13 (54%) compounds, human CL int, in vivo was predicted with a 3-to 10-fold error.
Relationship of elimination half-life (t 1/2 ) between humans and PXB mice Fig. 6 shows the relationship of t 1/2 after i.v. administration between humans and PXB mice.
Compounds for which literature data were not available were excluded from this figure. A good correlation (r 2 =0.886, p=1.506 x 10 -4 ) was found. For 6 of 9 (67%) compounds, human observed t 1/2 was predicted within 3-fold error from PXB mice t 1/2 . For 3 of 9 (33%) compounds, the error was in the range of 3-to 10-fold.
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Discussion
The prediction of human PK parameters is an important step during pre-clinical development of pharmaceuticals, in order to reduce costs by enabling early elimination of candidates with unsuitable properties. However, species differences make it difficult to predict human PK from animal data; monkey data may lead to under-prediction ( , 2010) . In this study, we checked metabolic activities (CYP2C9, CYP2D6, UGT, SULT, AO) using probe substrates between the donor hepatocytes and h-hepatocytes purified from PXB mice (Supplemental Table 3 For the present study, we selected 13 model compounds with diverse chemical structures ( Fig.   1 ), which are metabolized through multiple pathways by CYP and non-CYP enzymes, such as UGT, SULT, and aldehyde oxidase (AO). Their values of CL cover a wide range from 0.055 to 118 mL/min/kg (Table 1) . We used PXB mice which showed that the average RI values were about 80%. It was a concern that the contribution of remaining about 20% mice hepatocytes which may be reflected on clearance. CL int, in vitro of these model compounds in host mice hepatocytes (SCID mice) almost showed higher than those of h-hepatocytes within 10-fold range (Supplemental Fig.1 ). The extent of difference may not influence on predictability of CL int, in vivo.
For the estimation of CL int, in vivo in PXB mice, the plasma unbound fraction ( We assumed that blood/plasma concentration ratio (Rb) of those model compounds is also the same as in humans, since Rb values of some compounds (dapsone, diclofenac, ketoprofen, salbutamol, zaleplon) in this study were also approximately similar to those of human (data not shown).
Qh were assumed to be 90 mL/min/kg, respectively, corresponding to the values of normal mice (Davies et al., 1993) . In further work, it would be desirable to examine whether these This article has not been copyedited and formatted. The final version may differ from this version. values are appropriate.
In this study, we selected model compounds metabolized not only by CYP, but also by non-CYP enzymes, including aldehyde oxidase (AO). 6-Deoxypenciclovir, fasudil, sulindac, and zaleplon are mainly metabolized by AO in humans. It has been reported that human CL for drugs metabolized by AO may be underpredicted from data obtained with human liver cytosol and S9 due to loss or deactivation of AO during preparation, homogenization, storage and experimental procedures (Zientek et al., 2010) . PXB mice have high AO activity, being similar to humans (Kitamura et al., 2008) , and may be a useful source of fresh h-hepatocytes.
Our results indicate that PXB mice can at least be used for semi-quantitative prediction of not only CL t , but also t 1/2 in humans. PXB mice would also be useful for in vitro estimation and comparison of PK of various candidate compounds, since large amounts of fresh, identical hepatocytes (1.1x10 8 cells/mouse) are available by transplantation of donor hepatocytes (2.5x10 5 cells/mouse). The combination of in vitro study in PXB mice and in vitro study using PXB hepatocytes may prove to be particularly effective.
This article has not been copyedited and formatted. The final version may differ from this version. Table 4 In vivo intrinsic clearance (CL int, in vivo ) of humans and PXB mice , calculated by well-stirred model CL int, in vivo was calculated from the in vivo CL t , fu, Rb, and average hepatic blood flow (Q) based on a well-stirred model. Average hepatic flow (Q) of humans and PXB mice were set at 21 and 90 mL/min/kg (same as in normal mice), respectively. In addition, Rb and fu of human were assumed to be equivalent to those of PXB mice. If total CL of drugs exceeded liver blood flow, the hepatic clearance was taken as 90% of liver blood flow. CL int, in vivo of 6-deoxypenciclovir, lamotrigine, and sulindac were evaluated from oral clearance (CL oral ) as CL oral /fu. 
